Mucodyne

Quick links to important sections

Mucodyne

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mucodyne

Property Description
Active ingredient Carbocisteine (S-Carboxymethyl-L-cysteine)
Form Syrup, oral solution, tablets, or capsules
Pharmacological class Mucolytic agent
Common use Modifying and clearing excessive/viscous mucus
Origin Synthetic derivative of L-cysteine

1. What Type of Medicine is Mucodyne (Carbocisteine)?

Mucodyne is the trade name for a medicinal product containing the sole active ingredient, Carbocisteine. It is classified as a mucolytic agent and sits within the broader group of mucoactive medicines used to manage secretions in the respiratory tract. The active substance, Carbocisteine, is a synthetic derivative of the naturally occurring amino acid L-cysteine. Carbocisteine works primarily to change the composition of secretions rather than just increasing their volume to help manage thick mucus.


2. Physical Forms and General Purpose

Carbocisteine is intended for oral administration and is supplied in various pharmaceutical preparations, which commonly include liquid forms such as an oral solution or a syrup, alongside solid forms like tablets or capsules. The availability of both liquid and solid preparations ensures flexibility for administration across different age groups, including the paediatric population. The general therapeutic goal of this medicine is to support easier breathing and general comfort by modifying and facilitating the expulsion of abnormally thick or excessive mucus that accumulates in the breathing passages. Carbocisteine is used to relieve respiratory symptoms through its action on mucus.


3. The Chemical Basis of Mucolytic Action

The primary function of Carbocisteine is to act as a mucus modifier by directly addressing the high viscosity of respiratory secretions. The core mechanism involves the disruption of chemical links, specifically disulfide bonds, within the structure of mucin glycoproteins, the large molecules that give mucus its dense, sticky quality. This targeted chemical action transforms the thick secretions into a more fluid consistency, which in turn supports the body's natural mucociliary clearance system. This makes it an adjunctive therapy aimed at resolving the issue of mucus hyperviscosity.

What side effects are possible with Mucodyne?

Possible Side Effects and Safety Information for Mucodyne (Carbocisteine)

The official safety documentation for Mucodyne (carbocisteine) identifies its primary safety concerns in the gastrointestinal and skin/immune systems.

Serious and Clinically Significant Adverse Reactions

Mucodyne must be discontinued immediately if the following severe adverse reactions occur:

  • Gastrointestinal Bleeding: This may manifest as blood in the vomit or black, tarry stools.
  • Severe Cutaneous Reactions: Rare but serious skin disorders, including Stevens-Johnson syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Erythema Multiforme.
  • Anaphylactic Reactions: Severe, life-threatening allergic reactions.

Common and Frequency Not Known Adverse Reactions

Adverse reactions involving the gastrointestinal tract are the most frequently reported. The frequency of many effects, including serious ones, is officially categorized as Frequency not known from regulatory reports.

System-Organ Class Examples of Adverse Reactions (Frequency Not Known)
Gastrointestinal Nausea, vomiting, diarrhoea, epigastric discomfort, gastrointestinal bleeding.
Skin & Immune System Rashes, allergic skin reactions, headache, anaphylactic/anaphylactoid reactions, fixed drug eruption.

Safety Restrictions and Population-Specific Considerations

  • Contraindications: Mucodyne is contraindicated in patients with a known hypersensitivity to the active substance or excipients, and in patients with active peptic ulceration (gastric or duodenal ulcer).
  • Caution: Use requires caution in elderly patients and in individuals with a history of gastroduodenal ulcers or those taking concurrent medications known to cause gastrointestinal bleeding. If bleeding occurs, treatment must stop.
  • Pregnancy and Breast-feeding: Use is not recommended, particularly during the first trimester, due to insufficient safety data. Official documents state that the drug should only be used if deemed essential by a physician.
  • Paediatric Use: Use of the capsule formulation is not recommended for children under 18 years; the syrup formulation is contraindicated for children less than two years of age.

Overdose and Emergency Response

Mucodyne Overdose and When to Seek Help

Mucodyne, which contains the active ingredient carbocisteine, is generally considered to have a wide margin of safety. In the event of an overdose, the most likely symptoms are related to the gastrointestinal system, resulting from the ingestion of a large amount of the medication.

Key symptoms of Mucodyne overdose primarily involve gastrointestinal upset, including:

  • Nausea
  • Vomiting
  • Diarrhea
  • Epigastric discomfort (pain or discomfort in the upper abdomen)

When to Seek Immediate Medical Attention

If an overdose is suspected, even if the person appears well, it is vital to contact a poison control center or seek emergency medical services immediately. Medical professionals can provide supportive care and monitor for any complications.

While rare, certain serious symptoms require immediate emergency care as they may indicate a severe reaction or complication, such as gastrointestinal bleeding. Seek emergency medical help right away if you observe any of the following:

  • Blood in the vomit
  • Black, tarry stools (which may be a sign of internal bleeding)
  • Signs of a severe allergic reaction (e.g., swelling of the face, lips, tongue, or throat, or difficulty breathing)
  • Blistering or peeling of the skin, especially around the eyes, nose, mouth, or genitals (potential severe skin reaction)

In the event of an overdose, always take the drug packaging with you to the medical facility to provide the healthcare team with complete information on the product ingested.

Therapeutic Uses of Mucodyne

What Mucodyne Treats: Main Uses and Benefits

Mucodyne is commonly used in situations involving certain distressing symptoms related to excessive, thick mucus. The medication is used to address symptoms related to respiratory tract disorders characterized by the presence of excessive, viscous mucus. Its use is indicated when supportive symptom management is needed, particularly for chronic conditions like Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis, as well as during the acute phase of certain infections like tracheitis.

The medicine is applied when symptoms become more disruptive during flare-ups, especially a persistent, productive cough associated with thick sputum. It assists with easing the symptoms related to difficult expectoration (coughing up mucus). This generally helps ease the overall symptom load and supports the patient during difficult episodes by easing distress associated with a congested cough. In specific paediatric contexts, it is relevant for managing conditions like serous otitis media (glue ear), where it may assist with managing symptoms that create noticeable physiological strain.


Quick Fact: Relevant for Thick Mucus Symptoms Mucodyne is considered relevant for managing excessive, thick secretions, helping to address symptoms that create noticeable physiological strain.

Regulatory References

  1. Carbocisteine 375 mg Capsules, Hard - Summary of Product Characteristics

Eligibility and Restrictions for Use

Who Can and Cannot Use Mucodyne? — Official Regulatory Information

Regulatory documents establish clear criteria for the use of Mucodyne (carbocisteine) based on absolute prohibitions and restrictions for specific populations and conditions.


Category Eligibility Status (Official Regulatory Statement)
Absolute Contraindications Must NOT use if there is active peptic ulceration (gastric or duodenal ulcer) or known hypersensitivity to carbocisteine or any excipients.
Age-Related Contraindicated in children under 2 years of age. Approved for most adults and children aged 2 years and over.
Pregnancy/Lactation Not Recommended. Use is not recommended in pregnant women (especially the first trimester) or breastfeeding women due to insufficient human safety data.
Use with Caution Special caution is advised for the elderly and patients with a history of gastro-duodenal ulcers. Discontinue immediately if gastrointestinal bleeding occurs.
Excipient Restrictions Must not take formulations containing specific sugars (e.g., lactose or maltitol) if diagnosed with related rare hereditary metabolic disorders (e.g., total lactase deficiency).

What should I know about interactions with other medicines?

The interaction profile for Mucodyne (Carbocisteine) is structured around pharmacodynamic conflicts and caution related to co-administration risk, rather than formal pharmacokinetic (PK) interactions. Many regulatory sources indicate that no specific PK interactions involving liver enzymes or drug transporters have been formally documented.

Interaction-Related Restrictions

Pharmacodynamic Antagonism

The core regulatory restriction involves substances that conflict with the medicine's primary action. Co-administration with antitussives (cough suppressants) or medicinal products for drying respiratory secretions (such as Atropine-like agents) is classified as an irrational combination and is restricted. This prohibition is due to the opposing actions of these medicinal products, which would counteract the mucolytic effect and impede the natural clearance of secretions.

Population-Specific Caution

A critical, condition-specific constraint is noted regarding the risk of gastrointestinal bleeding. Caution is required during the co-administration of Carbocisteine with any medications known to cause gastrointestinal bleeding (e.g., non-steroidal anti-inflammatory drugs or antiplatelets). This constraint is particularly emphasized for the elderly population and for individuals who have a documented history of gastroduodenal ulcers. This requirement addresses the increased risk of gastrointestinal adverse effects when combining such agents. No timing-based separation rules for co-administration are documented in the official labeling.

Mechanism of Action

How Mucodyne Works — Mechanism of Action

Mucodyne (carbocisteine) functions as a muco-regulator by acting intracellularly on respiratory tract goblet cells. The drug modulates the activity of key enzymes, specifically by promoting sialyltransferase. This intracellular process shifts the relative balance of secreted mucin glycoproteins, increasing the proportion of low-viscosity sialomucins while decreasing high-viscosity fucomucins. The resultant change in mucus composition causes a reduction in the viscosity and elasticity of the airway secretions.

This altered fluid characteristic improves the rheological properties of the mucus layer, which, in turn, supports the mechanical function of the mucociliary escalator for enhanced fluid transport and clearance. Additionally, carbocisteine demonstrates ancillary mechanisms, including acting as a free-radical scavenger and suppressing key pro-inflammatory signaling pathways (such as NF-kappaB) within the respiratory epithelium. This contributes to the attenuation of localized oxidative stress and inflammatory signaling.

Dosage and Administration Information

The use of Carbocisteine (Mucodyne) is based on an oral administration protocol. The regimen is structured into two main phases: an initial higher daily dose followed by a reduced maintenance dose.

Dosing Regimen

The total daily amount for adults and the elderly typically begins at 2250 mg and is administered in divided doses throughout the day. Upon achieving a satisfactory response, the regimen shifts to a maintenance dose, usually 1500 mg per day, also taken in divided intervals. The medicine may be taken with or without food.

Administration by Formulation and Age

Mucodyne is available as capsules, tablets, and oral solutions or syrups. The choice of formulation is guided by the patient's age and ability to swallow, ensuring the administration is consistently oral. Capsules should be swallowed whole. For all liquid forms, the use of a provided measuring device, such as a cup or syringe, ensures the dose is accurately measured.

Dosing for the paediatric population (children aged 2 to 12 years) is determined by age and/or body weight, and these patients are administered the oral solution; adult solid forms are not recommended. If a dose is missed, the standard approach is to skip the missed dose if the next one is due shortly; a double dose must never be taken.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Mucodyne (Carbocisteine)


Evidence for Use in Chronic Obstructive Pulmonary Disease (COPD)

Research has examined carbocisteine in adult patients with conditions associated with acute or disruptive episodes, such as Chronic Obstructive Pulmonary Disease (COPD). The primary research scenarios involve Randomized Controlled Trials (RCTs), where carbocisteine was studied for use compared to a placebo (an inactive treatment). These studies monitored patients over intermediate to long periods, sometimes lasting up to a year. The main outcomes related to systemic or functional imbalance that researchers studied for included the annual number of COPD flare-ups or exacerbations, and patient-reported outcomes describing perceived discomfort and quality of life using standardized questionnaires.

Studies reported patterns observed in the group receiving carbocisteine regarding the rate of COPD exacerbations compared to the placebo group. Studies also reported measurements of quality of life scores taken during the study period. Some studies reported measurements of lung function parameters like FEV1, but the data regarding these measurements were mixed.


Evidence for Use in Chronic Bronchitis and Viscous Mucus

Carbocisteine was evaluated in patients with conditions characterized by fluctuating or episodic manifestations where excessive viscous mucus is a factor, such as chronic bronchitis. Research in this area primarily includes older clinical trials and short-term RCTs. Studies examined the physical properties of sputum to see if patterns were related to the use of carbocisteine. Researchers also examined outcomes like the patient’s reported ease of expectoration during the study period.

Studies reported measurements of the properties of sputum that were taken during the study period. Comparative evidence against other symptomatic care is limited in the published research.


What is Still Uncertain About Carbocisteine Evidence

Evidence highlights what is known — and what is still uncertain — about carbocisteine. One key area is the lack of consistency across all studies, meaning findings were mixed on certain outcomes like measurements of lung function. Limited information is available for long-term outcomes beyond the periods studied in the major trials. Data for certain groups remain insufficient, and research is ongoing to better understand its role in certain conditions like bronchiectasis.

Frequently Asked Questions (FAQ)

Common questions about Mucodyne (FAQ)

Q: How quickly should I expect Mucodyne to start working?

A: Regulatory documents describe how the drug is absorbed by the body. Official information indicates that the active substance, carbocisteine, is rapidly taken up, and the highest concentrations of the substance in the blood are measured at approximately two hours after administration.


Q: Is Mucodyne a type of antibiotic?

A: No, official sources classify the main drug in Mucodyne (carbocisteine) as a mucolytic agent. The substance is classified as a mucolytic agent, and its function involves modifying and thinning mucus, which is distinct from the action of an antibiotic.


Q: Can Mucodyne be used for a dry cough?

A: The substance is described as functioning to modify and reduce the viscosity of secretions associated with conditions like a productive cough. Official product information is generally focused on its use for respiratory tract disorders characterized by excessive, viscous mucus.


Q: Can children use Mucodyne, and if so, at what age?

A: Official documents define the authorized population for the oral solution as children, typically within the ages of 2 to 12 years. Regulatory documents state that the medicine is specifically contraindicated (should not be used) for children who are less than two years old.


Q: Is it safe to take Mucodyne if I am pregnant?

A: Official product information states that use during pregnancy is generally not recommended, especially in the first trimester, due to a lack of sufficient safety data. Regulatory guidance states that the drug is indicated for use only if a prescribing healthcare provider considers it essential.


Q: Can I take Mucodyne while I am breastfeeding?

A: According to regulatory information, use while breastfeeding is not recommended because there is insufficient data available on the presence of the drug in human milk. Regulatory guidance states that the drug is indicated for use only if a prescribing healthcare provider considers it essential.


Q: Is there a risk of drowsiness or feeling tired when taking Mucodyne?

A: The drug is described in official documents as having no or negligible influence on the ability to drive or use machines.


Q: Is there any research on long-term safety of using Mucodyne?

A: Studies have examined the use of the drug over intermediate to long periods, sometimes lasting up to a year. Official product information notes that limited information is available regarding long-term outcomes and evidence beyond the study periods reported in the major clinical trials.


Q: What kind of studies have been done on Mucodyne's effectiveness?

A: Research has primarily involved Randomized Controlled Trials (RCTs) against a placebo. These trials monitored outcomes such as the annual number of respiratory flare-ups, changes in patient-reported quality of life, and measurements of sputum properties.


Q: Is there any warning about taking Mucodyne with cough suppressants?

A: Yes, regulatory documents include a warning that combining Mucodyne with antitussives (cough suppressants) is restricted. This restriction is due to the opposing actions of the products, which would counteract the mucolytic effect and impede the clearance of secretions.


Q: Can Mucodyne be crushed or mixed with food if swallowing is difficult?

A: Official instructions state that capsules should be swallowed whole. The liquid oral solution is the indicated alternative formulation for individuals who have difficulty swallowing pills, and the official instructions require the use of a provided measuring device.


Q: Is Mucodyne available over the counter or do I need a prescription?

A: The regulatory status of Mucodyne varies depending on the specific country and the formulation. Official product information indicates that some liquid forms are authorized for dispensing without a prescription for a short duration, while other forms and durations may require a prescription.


Q: How long does the effect of one dose of Mucodyne typically last?

A: The regulatory data on how quickly the drug is cleared from the body, known as the elimination half-life, is approximately two hours. This indicates the rate at which the body processes the dose over time.


Q: Are there different strengths or formulations of Mucodyne?

A: Yes, official product information confirms that the drug is available in different strengths and forms, such as 375 mg capsules, and oral solutions or syrups which typically contain 250 mg per 5 ml.


Q: What is the difference between Mucodyne and other cough medicines like 'Brand X'?

A: Official information classifies Mucodyne as a mucolytic agent, meaning it works to modify and thin mucus. This classification is distinct from cough suppressants, which work by suppressing the cough reflex.


Q: Can Mucodyne affect my ability to drive or operate machinery?

A: Regulatory documents state that the drug has no or negligible influence on the ability to drive or use machines.


Q: Is Mucodyne known to interact with herbal supplements?

A: Official regulatory documents generally state that no formal drug interactions have been identified for this medicine. However, information on potential interactions with specific herbal supplements is often limited or not stated.


Q: Are there any specific foods or drinks that should be avoided while taking Mucodyne?

A: There are no specific foods or drinks officially listed that must be avoided. However, the syrup formulation may contain ingredients like sucrose or sodium that require caution for patients with specific dietary restrictions (e.g., diabetics, low-sodium diets).


Q: Why is Mucodyne not recommended for all age groups?

A: It is not recommended for all age groups primarily because the syrup formulation is specifically contraindicated (should not be given) for children less than two years of age due to established safety limitations.


Q: Does taking Mucodyne help with ear congestion or just chest congestion?

A: The official indication for the drug is for respiratory tract disorders. These are conditions related to the lungs and airways, suggesting the intended use is for chest congestion rather than ear congestion.


Q: What is the scientific classification of the main drug in Mucodyne?

A: The active ingredient, carbocisteine, is formally classified under the ATC system (a global classification used by regulatory bodies) as a mucolytic agent.


Q: Are there any contraindications related to kidney or liver disease for Mucodyne?

A: The key contraindications listed in official documents focus on hypersensitivity and active peptic ulceration. Specific contraindications or warnings related to existing kidney or liver disease are not typically listed in these official sections.


Q: What is the recommended maximum duration for a course of Mucodyne?

A: Official guidance states that for some short-term use formulations, the maximum duration of treatment is restricted, typically not exceeding five days.


Q: Does Mucodyne interact with birth control pills?

A: The regulatory information regarding formal drug interactions consistently states that no drug interactions have been identified for this medicine, suggesting there is no documented conflict with oral contraceptives.


Q: Are there any warnings about combining Mucodyne with sedating medications?

A: Regulatory documents state the drug has no or negligible influence on the ability to drive or use machines. There are no specific warnings stated about combining it with sedating medications.

How should Mucodyne be stored and disposed of?

How to Store and Dispose of Mucodyne

Official regulatory documents define strict requirements for the storage and disposal of Mucodyne (Carbocisteine) to ensure product quality and safety.

Storage Requirements

Condition Requirement
Temperature Do not store above 25 C or 30 C (varies by formulation).
Handling Do not refrigerate or freeze the medicine.
Protection Keep the medicine protected from light.
In-Use Stability Discard oral solution after a specified period following opening (e.g., 15 days or 3 months).
Child Safety Keep this medicine out of the sight and reach of children.

Disposal

Any unused or expired Mucodyne must be disposed of in accordance with local requirements. This means returning it to a pharmacy or authorized collection point, rather than disposing of it in household trash or wastewater, unless otherwise instructed by local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Mucodyne found in:

A-Z Index: